Accueil › Cancer du poumon › Massachusetts › Worcester
Essais cliniques pour Cancer du poumon à Worcester, MA
11 études pour Cancer du poumon recherchent des participants dans et autour de Worcester (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Recrutement en coursPhase 3
- UMass Memorial Medical Center - University Campus, Worcester
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Recrutement en coursPhase 3
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional, Milford · à 17 mi
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Recrutement en coursPhase 3
- UMass Memorial Medical Center - University Campus, Worcester
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Recrutement en coursPhase 3
- UMass Memorial Medical Center - University Campus, Worcester
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Recrutement en coursPhase 3
- Reliant Medical Group Inc, Worcester
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Recrutement en coursPhase 3
- University of Massachusetts Memorial Medical Center, Worcester
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Recrutement en coursPhase 3
- UMass Memorial Medical Center - University Campus, Worcester
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Recrutement en coursPhase 2
- UMass Memorial Medical Center - University Campus, Worcester
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Recrutement en coursPhase 2
- UMass Memorial Medical Center - University Campus, Worcester
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Recrutement en coursPhase 2/3
- UMass Memorial Medical Center - University Campus, Worcester
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recrutement en coursÉtude observationnelle
- Massive Bio SYNERGY-AI site, Worcester
Essais pour Cancer du poumon dans d'autres villes
- Houston, TX78 études
- Boston, MA62 études
- New York City, NY60 études
- Los Angeles, CA45 études
- Washington, DC41 études
- Arlington, VA41 études
- Chicago, IL41 études
- Nashville, TN40 études
- Baltimore, MD40 études
- St. Louis, MO39 études
- Columbus, OH37 études
- Philadelphia, PA36 études
Autres études à Worcester
- Cancer du poumon non à petites cellules14 études
- Cancer (tous types)7 études
- Cancer du sein6 études
- Schizophrénie5 études
- Cancer métastatique5 études
- Cancer de la prostate5 études
- Cancer de l'ovaire5 études
- Trouble dépressif majeur5 études
- Dépression5 études
- Leucémie aiguë myéloïde5 études
- Carcinome urothélial (à cellules transitionnelles)4 études
- Cancer de la vessie4 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.